Re: How Should Helicobacter Pylori Eradication Be Performed in Cases of Extensive Allergies to Proton Pump Inhibitors? Reply

Yasin Şahin; Özlem Yılmaz

doi:10.5152/eurjther.2019.160519

Authors

Yasin Şahin Division of Pediatric Gastroenterology, Mersin City Training and Research Hospital, Mersin, Turkey https://orcid.org/0000-0002-7394-4884
Özlem Yılmaz Division of Pediatric Allergy, Mersin City Training and Research Hospital, Mersin, Turkey https://orcid.org/0000-0003-2971-283X

DOI:

https://doi.org/10.5152/eurjther.2019.160519

Keywords:

Helicobacter Pylori

Abstract

Dear Editor,

We appreciate the interest shown by Pellicano in our article (1) and for the valuable comments. We agree with Pellicano’s all comments. The vonoprazan is not available in Turkey, because of that we could not experience this new drug.
In conclusion, we wanted to emphasize that cross-reactivity be-tween proton pump inhibitors (PPIs) should be considered before HP treatment in patients with allergies to PPIs in our case report. The choice of treatment should be planned based on the results of allergic evaluations. In addition to that if there is an extensive allergies to PPIs or PPIs are not available, we also wanted to em-phasize that ranitidine can be safely used in a combined regimen of HP eradication therapy as suggested by Pellicano (1-4).

Metrics

Metrics Loading ...

References

Şahin Y, Yılmaz Ö. How should Helicobacter pylori eradication be done in the extensive proton pump inhibitor allergy? Eur J Ther 2019; 25: 89-92. https://doi.org/10.5152/EurJTher.2018.654

Cisarò F, Astegiano M, De Angelis C, Saracco G, Rizzetto M, Pellicano R. Ranitidine bismuth citrate in the first-line of Helicobacter pylori treatment. Panminerva Med 2011; 53: 138.

Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38: 243-70. https://doi.org/10.2165/00003088-200038030-00004

Pellicano R, Zagari RM, Zhang S, Saracco GM, Moss SF. Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol 2018; 64: 310-21. https://doi.org/10.23736/S1121-421X.18.02494-7